Relevant Articles About Research and Clinical Trials in Breast Cancer
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to examine the direct effects of combining nintedanib with anti-angiogenic agents on UM cell behavior. The results showed that nintedanib suppresses UM cell growth; further research is needed to explore therapeutic potential in UM....
KEY TAKEAWAYS The study aimed to investigate the spatial relationships between tumor-infiltrating leukocytes and lymphovasculature in primary human cutaneous melanoma. The study presented a platform mapping lymphovascular and immune infiltrates in primary melanoma,...
KEY TAKEAWAYS The study aimed to investigate the incidence of HH and its impact on outcomes following esophagectomy in esophageal adenocarcinoma patients. Researchers noticed that, despite higher postoperative complications in HH patients, low positive margin rates...
A phase II open-label clinical trial, BRCA1/2, NCT02401347, assessed the efficacy of Talazoparib in advanced HER2-negative breast cancer and other solid tumors. The …
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US …
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, …
Introduction: Spinal metastases are common in metastatic cancer, affecting around 40% of patients. The primary treatment involves radiation therapy, transitioning from conventional external beam radiation therapy (EBRT) to stereotactic body radiation therapy (SBRT) for its …